ADAURA Sentiment Analysis

Sentiment from Key Opinion Leaders regarding ADAURA Trial presented at #ASCO23

Total Impressions 910,582

ADAURA KOL Sentiment

Top Tweets

Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023 38.5% of people who had recurrence got OSI (very low!) That just isn't good enough Brain staging is suboptimal= occult met disease Would you let your mother be on the control arm and not get OSI on progression?	Hey @JackWestMD , did you already see p25 of the #ADAURA supplementary appendix? Curious of your thoughts given 88% of pts in the placebo arm who developed progression and were fit enough to get more tx got a TKI. #ASCO23 nejm.org/doi/suppl/10.1
Before we all continue to pile on #ADAURA , can someone tell me % of patients who received Immunotherapy upon progression on IM-010 or KN-91. See figure. I will remind you that immunotherapy alone or in combination is THE SOC for 1L Metastatic NSCLC. How come we don't see that being discussed? Let's really stop the misinformation here. Adjuvant osi helps people live longer. That is all.	My analysis of ADAURA now on youtube in high resolution #ASCO23 ADAURA OS - Control arm participants who progressed got poor medical car... youtu.be/lu2Kqw2Htho via @YouTube

Key Opinion Leader Sentiment Analysis of ADAURA Trial

Doctor Name	Sentiment	Comment
Stephen V Liu, MD	POSITIVE	Highlight of the #IULungSymposium is getting to hear Dr. Larry Einhorn discuss the field. Poses critical questions for the field. One of the great speakers in thoracic oncology. #LCSM https://t.co/BrpOk63tLy
Nathan A. Pennell MD, PhD, FASCO	POSITIVE	Thanks to @VivekSubbiah for giving @JackWestMD and I a chance to channel our debates into surprising consensus! #LCSM Lessons from ADAURA: Can we improve on a positive trial? - West and Pennell - Cancer https://t.co/3h47aR03gd
Jonathan Spicer MD PhD	POSITIVE	#ALINA, #ADAURA and #KN671 were all smiles today @myESMO #ESMO23! Love these guys! https://t.co/094rK9iW1B
Charu Aggarwal, MD, MPH, FASCO	POSITIVE	@christine_lovly @Alexmenter @ASCO @OncoAlert @OncBrothers @JackWestMD I see that using the word “cure” makes oncologists uncomfortable. The curves above show that we are undeniably improving survival. https://t.co/xWdKhfa03s
Christine Lovly, MD, PhD	POSITIVE	@Alexmenter @CharuAggarwalMD @ASCO @OncoAlert @OncBrothers Agree! I am very enthusiastic about the ADAURA data. But can we truly say “cure” with the available data? @JackWestMD
Balazs Halmos, MD	POSITIVE	#ASCO23 ADAURAble results! How it started How it is going 👇 👇 https://t.co/WuvwSG6qn6
H. Jack West, MD	NEUTRAL	🚨That also doesn't factor in that the patients directed to adjuvant chemo almost certainly had higher risk disease, while those who didn't were enriched for more favorable disease features. Know that if you don't recommend adjuvant chemo, you're undertreating. https://t.co/73QGsmEhzd
Jeff Ryckman, MD	NEGATIVE	@MassimoDiMaio75 Love how the response is that "data suggest that the greatest overall survival benefit is achieved with the use of adjuvant osimertinib, as supported by the results of the ADAURA and FLAURA trials" ...as if there were a trial of salvage vs. adjuvant osimertinib?? The prevailing… https://t.co/vgdEtbAKbo
Vinay Prasad MD MPH	NEGATIVE	#adaura has dozens and dozens of authors. Fda onc hundreds of employees. Not a single one of them fought for the control arm patients. Now control on patients have to litigate. I don't disagree, but it is amazing. #asco23 https://t.co/Qna3mYVfiW
Vladmir C. Cordeiro de Lima, MD, PhD	NEGATIVE	@JackWestMD 👍When you're about to present a potentially paradigm-shifting study, you better make all effort to leave no room for questioning. In this particular case: no PET / brain RM before osi initiation, adjv chemo at invest discretion, OS as 2nd endpoint, no mandatory crossover at PD.
H. Jack West, MD	NEGATIVE	Helpful background. But AZ promoted osi as clear optimal 1L SOC for relapsed/adv EGFRm+ NSCLC since 2017 presentation of ADAURA, & osi was longstanding 1L SOC in US & much of ROW long before 4/2020. IMO, disngenuous to say that while not yet offering to pts w/relapse in ctrl arm. https://t.co/MavabLw2mU

ASCO23, lung cancer